Jim Cramer recently discussed Eli Lilly and Company (NYSE:LLY) as one of his top pharmaceutical stocks. He praised the firm for its weight loss drugs, manufacturing plans in America, and new drugs in the pipeline. However, he noted that the firm needs catalysts for further gains, despite surpassing third-quarter estimates.

While LLY shows investment potential, some believe that AI stocks offer greater promise for higher returns with limited downside risk. For those seeking an affordable AI stock benefiting from Trump tariffs and onshoring, a report on the best short-term AI stock is available.

Looking for stock opportunities? Check out “30 Stocks That Should Double in 3 Years” and “11 Hidden AI Stocks to Buy Right Now” for potential investments. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Eli Lilly (LLY) Would Be Up More If The Market Weren’t That Bad, Says Jim Cramer